Save time and jump to the most important pieces.
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.Turner Pope Investments (TPI) Ltd will be the Company's sole broker.For further information, please contact:Midatech Pharma PLCStephen Stamp, CEO, CFOTel: +44 (0) 29 2048 0180www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser)James Dance / Matthew Chandler / Rob PatrickTel: +44 (0)20 7409 3494 Turner Pope Investments (TPI) Ltd (Broker)Andre
Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Offic
ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.BackgroundMany cancers exhibit high levels of metabolic plasticity, i.e. the ability to switch between energy-generating pathways in response to cellular stresses[1], such as those caused by chemotherapy. Highly proliferative cancers frequently use the aerobic glycolysis pathway, known as "the Warburg effect", to generate energy2. Oxidat
Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Company's Shareholder Circular and Notice of General Meeting (the "Circular") which
Midatech Pharma PLC ("Midatech" or the "Company") Further re: Notice of General Meeting - Correction of Typographical ErrorsABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:· Resolution 4 of the Notice ("Resolution 4") refers to a proposed aut
Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information.The
6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
Gainers electroCore (NASDAQ:ECOR) shares increased by 27.9% to $5.47 during Friday's regular session. As of 13:30 EST, electroCore's stock is trading at a volume of 91.3K, which is 434.3% of its average full-day volume over the last 100 days. The company's market cap stands at $25.9 million. Concord Medical Services (NYSE:CCM) shares rose 22.72% to $1.35. The company's market cap stands at $58.6 million. Vicarious Surgical (NYSE:RBOT) stock moved upwards by 20.03% to $1.8. As of 13:30 EST, this security is trading at a volume of 1.4 million shares, making up 378.4% of its average full-day volume over the last 100 days. The company's market cap stands at $226.7 million. Virios Therapeutic
On Friday, 469 companies hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Bank of America (NYSE:BAC). TC BioPharm (Holdings) (NASDAQ:TCBP) was the smallest firm by market cap to set a new 52-week low. Silvergate Capital (NYSE:SI) made the largest move down on the session, with shares plummeting 74.5% to reach its 52-week low. BlackRock TCP Cap (NASDAQ:TCPC) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. On Friday, the following stocks hit new 52-week lows: Bank of America (NYSE:BAC) stock hit a yearly low of $26.32. The stock was down 2.21% fo